WO2023208092 - TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF

National phase entry:
Publication Number WO/2023/208092
Publication Date 02.11.2023
International Application No. PCT/CN2023/091076
International Filing Date 27.04.2023
Title **
[English] TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF
[French] DÉRIVÉS HÉTÉROCYCLIQUES TRICYCLIQUES, COMPOSITIONS ET UTILISATIONS DE CEUX-CI
Applicants **
DANATLAS PHARMACEUTICALS CO., LTD. Suite 101, Floor 2, Building 2-4A, 7#, Liangshuihe 1st Street, BDA Daxing District, Beijing 100176, CN
Inventors
ZHOU, Wenlai Suite 101, Floor 2, Building 2-4A, 7#, Liangshuihe 1st Street, BDA Daxing District, Beijing 100176, CN
ZHUO, Jincong Suite 101, Floor 2, Building 2-4A, 7#, Liangshuihe 1st Street, BDA Daxing District, Beijing 100176, CN
YAN, Dan Suite 101, Floor 2, Building 2-4A, 7#, Liangshuihe 1st Street, BDA Daxing District, Beijing 100176, CN
YU, Zhangqi Suite 101, Floor 2, Building 2-4A, 7#, Liangshuihe 1st Street, BDA Daxing District, Beijing 100176, CN
ZHANG, Yao Suite 101, Floor 2, Building 2-4A, 7#, Liangshuihe 1st Street, BDA Daxing District, Beijing 100176, CN
Priority Data
PCT/CN2022/131223   10.11.2022   CN
PCT/CN2022/135765   01.12.2022   CN
PCT/CN2023/089128   19.04.2023   CN
PCT/CN2022/000075   28.04.2022   CN
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
*
International Searching Authority
*
Applicant's Legal Status
*
*
*
*
*
Entry into National Phase under
*
Translation

Recalculate

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing4133
EPO Filing, Examination26801
Japan Filing589
South Korea Filing672
USA Filing, Examination13510
MasterCard Visa

Total: 45705

The term for entry into the National Phase has expired. This quotation is for informational purposes only

Abstract[English] The disclosure relates to tricyclic heterocyclic derivatives as shown in Formula (I), to pharmaceutical compositions comprising them, to a process for their preparation, and their use as therapeutic agents.[French] L'invention concerne des dérivés hétérocycliques tricycliques tels que représentés dans la formule (I), des compositions pharmaceutiques les comprenant, un procédé permettant leur préparation, et leur utilisation en tant qu'agents thérapeutiques.
An unhandled error has occurred. Reload 🗙